{
    "clinical_study": {
        "@rank": "90952", 
        "brief_summary": {
            "textblock": "OBJECTIVES: I.  Evaluate migraine prophylaxis with soy protein isolate in patients with\n      hereditary hemorrhagic telangiectasia.\n\n      II.  Assess whether soy protein isolate reduces the frequency and severity of epistaxis and\n      gastrointestinal bleeding in these patients."
        }, 
        "brief_title": "Phase III Randomized, Placebo-Controlled, Crossover Study of Soy Protein Isolate for Hereditary Hemorrhagic Telangiectasia", 
        "condition": "Hereditary Hemorrhagic Telangiectasia", 
        "condition_browse": {
            "mesh_term": [
                "Telangiectasia, Hereditary Hemorrhagic", 
                "Telangiectasis"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a randomized study. One group of patients is treated with soy\n      protein isolate for 12 weeks.  The control group receives a placebo for 12 weeks.\n\n      Patients cross to the alternate group following a 4-week washout."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  Hereditary hemorrhagic telangiectasia (HHT) with 2 of the following:\n\n          -  First-degree relative with HHT\n\n          -  History of recurrent epistaxis or gastrointestinal bleeding\n\n          -  Three or more skin telangiectasia\n\n          -  Migraine headache meeting International Headache Society criteria 3 or more times a\n             month for more than 1 year\n\n          -  No pattern of daily headaches\n\n          -  No severe head trauma\n\n          -  No onset of headaches after 50 years of age\n\n          -  At least 1 month since migraine prophylaxis\n\n          -  At least 1 month since any of the following medications: Beta blockers; Calcium\n             channel blockers; Divalproex sodium; Tricyclic antidepressants; Selective serotonin\n             re-uptake inhibitors\n\n          -  Concurrent regular treatment for migraine and gastrointestinal hemorrhage allowed\n\n          -  Creatinine no greater than 2.5 g/dL\n\n          -  No allergy to soy\n\n          -  No pregnant women\n\n          -  No women with intent to become pregnant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "15 Years"
        }, 
        "enrollment": "60", 
        "firstreceived_date": "February 24, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004654", 
            "org_study_id": "199/11799", 
            "secondary_id": "YALESM-8191"
        }, 
        "intervention": {
            "intervention_name": "soy protein isolate", 
            "intervention_type": "Drug"
        }, 
        "keyword": [
            "genetic diseases and dysmorphic syndromes", 
            "hematologic disorders", 
            "hereditary hemorrhagic telangiectasia", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "Yale University", 
            "last_name": "Joshua R. Korzenik", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 3", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004654"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "collaborator": {
                "agency": "Yale University", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Center for Research Resources (NCRR)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "January 1996", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2001"
    }, 
    "geocoordinates": {}
}